Revolution Medicines, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Revolution Medicines, Inc. (RVMD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $364.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-25
- Revolution Medicines, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $364.60M, a 94.76% increase from fiscal 2024.
- Revolution Medicines, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $187.20M, a 22.67% increase from fiscal 2023.
- Revolution Medicines, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $152.60M, a 89.10% increase from fiscal 2022.
- Revolution Medicines, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $80.70M, a 37.24% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $364.60M 10-K · filed 2026-02-25 |
| 2024-12-31 | $187.20M 10-K · filed 2026-02-25 |
| 2023-12-31 | $152.60M 10-K · filed 2026-02-25 |
| 2022-12-31 | $80.70M 10-K · filed 2025-02-26 |
| 2021-12-31 | $58.80M 10-K · filed 2023-02-27 |
| 2020-12-31 | $37.30M 10-K · filed 2022-02-28 |
| 2019-12-31 | $12.60M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |